You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

SHINGRIX mechanism of action

SHINGRIX is designed to induce cellular and humoral immune responses to VZV 1*

SHINGRIX combines a non-live antigen with an Adjuvant System 1*

Go to Close Top

Visual shows the interaction of the antigen and adjuvant components of SHINGRIX. For any additional questions please call GSK customer service at 1-800-387-7374.

Non-live

ANTIGEN

Glycoprotein E (gE)

ADJUVANT SYSTEM

AS01B

Elicits immune responses to VZV 1

Enhances the immune response to the vaccine antigen 1

  • A major glycoprotein from VZV
  • Unable to replicate
  • Induces local and transient activation of the innate immune response
  • Facilitates the recruitment and activation of antigen-presenting cells

SHINGRIX is designed to help induce antigen-specific immune responses in individuals with pre-existing immunity against the varicella zoster virus (VZV) 1

* Clinical significance has not been established.

Reference:

  1. SHINGRIX Product Monograph. GlaxoSmithKline Inc., October 13, 2017.